# Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells

> **NCT04628806** · — · UNKNOWN · sponsor: **Charite University, Berlin, Germany** · enrollment: 120 (estimated)

## Conditions studied

- Melanoma Stage IV
- Sarcoma
- Squamous Cell Carcinoma
- Pancreatic Cancer Stage IV
- Prostate Cancer
- Breast Cancer Stage IV

## Interventions

- **DIAGNOSTIC_TEST:** CTC isolation by HSP70

## Key facts

- **NCT ID:** NCT04628806
- **Lead sponsor:** Charite University, Berlin, Germany
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-17
- **Primary completion:** 2022-02
- **Final completion:** 2022-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2021-05-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04628806

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04628806, "Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04628806. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*